mechanisms of antigen escape following cd19-directed car-t therapy
Published 2 years ago • 111 plays • Length 3:01Download video MP4
Download video MP3
Similar videos
-
1:40
overcoming antigen escape following cd19-directed car-t therapy
-
1:53
the detection and management of mnts following bcma-directed car-t therapy
-
2:49
cd19 car-t therapy drives the expansion of clonal hematopoiesis and associated cytopenias in lbcl
-
1:21
the role of microglia in the pathophysiology of icans following cd19 car-t therapy
-
1:35
key mechanisms of resistance to car t-cell therapy
-
3:57
mechanisms and management of short- and long-term car-t toxicities
-
3:38
mechanisms of resistance to car-t in all: t-cell fitness, antigen loss and immunological rejection
-
1:55
using single-cell multiomics to predict patients at risk for antigen escape after car-t therapy
-
3:02
euplagia-1: phase i trial of glpg5201, a cd19 car-t product, in r/r cll and richter's transformation
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
1:55
exploring first-line car-t therapy for the treatment of dlbcl
-
0:50
improving car-t cell efficacy: optimizing car constructs and counteracting tumor escape
-
1:14
components of the car-hematotox model which allow for prediction of icaht following car-t
-
2:10
managing hematologic toxicity associated with car-t therapy & insights into the car-hematotox score
-
2:42
dual-targeted anti-cd19/anti-cd20 car t-cells in r/r mcl: insights from a phase i/ii trial
-
3:06
repeat infusions of cd19 car-t
-
3:31
a summary of the prognostic factors that can influence the outcomes of anti-cd19 car-t in r/r dlbcl
-
2:20
risk factors for success or failure of cd19-directed car-t therapy in children with b-all